AUS
NZ
UK
CA
USA
IND
Highlights
- Elevai Biosciences has released data on a dual-action blocker, EL-32, for muscle and fat composition.
- Preclinical studies on aged mice indicated improved strength, motor function, and body composition.
- Further animal studies are planned for future advancements in research.
Elevai Biosciences, a subsidiary of Elevai Labs Inc. (NASDAQ:ELAB), focuses on developing treatments that target muscle and fat regulation. The company recently shared preclinical results from its research on EL-32, a compound designed to block both myostatin and activin-A. These proteins play a role in muscle degeneration and fat accumulation, making EL-32 a subject of interest in the field of metabolic health.
Preclinical Results for EL-32
In preclinical studies conducted on aged mice, Elevai Biosciences tested EL-32 over an extended period to observe its effects on muscle strength and overall body composition. The results showed promising improvements in grip strength, motor function, and fat reduction. These findings suggest that the dual-action blocker may help preserve muscle mass while managing fat levels, a significant breakthrough in this sector.
Focus on Obesity and Muscle Preservation
EL-32's development aligns with the company's broader interest in addressing metabolic disorders like obesity. The research indicates that the compound, when used with GLP-1 receptor agonists, could potentially aid in fat reduction while maintaining muscle mass. The combination of preserving muscle and reducing fat is a vital focus area in obesity treatment.
Planned Future Studies
Elevai Biosciences aims to further its research with additional animal studies, planning to move towards an Investigational New Drug (IND) application. These studies will provide more data on the long-term safety and efficacy of EL-32.
